Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires?

Core Insights - Cogent Biosciences Inc. is recognized as a promising multibagger stock by billionaires, with significant regulatory momentum following positive pivotal trials for its lead candidate, bezuclastinib [1][2] - The company has submitted an NDA for Non-Advanced Systemic Mastocytosis and plans to submit another NDA for Advanced Systemic Mastocytosis in the first half of 2026 [1] - Cogent is also pursuing a rolling NDA for second-line gastrointestinal stromal tumors under the FDA's Real-Time Oncology Review program, with completion expected by April 2026 [2] Financial Position - Cogent ended 2025 with $900.8 million in cash and marketable securities, bolstered by a $546.8 million public offering in late 2025, which is projected to fund operations into 2028 [3] Product Pipeline - Beyond bezuclastinib, Cogent is advancing a diverse pipeline of selective inhibitors, including CGT1145 for JAK2-driven diseases and CGT1815 for KRAS-mutant cancers, with multiple IND applications planned for the coming year [3][4]